ACRX - アセルRX・ファ―マシュ―ティカルズ (AcelRx Pharmaceuticals Inc.) アセルRX・ファ―マシュ―ティカルズ

 ACRXのチャート


 ACRXの企業情報

symbol ACRx
会社名 AcelRx Pharmaceuticals Inc (アセルRX・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 AcelRx Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04 Zalviso which utilize sublingual sufentanil delivered through a non-invasive route of administration and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation anxiety reduction and pain relief for patients undergoing painful procedures in a physician''s office. It also includes ARX-02 which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.   アセルRX・ファ―マシュ―ティカルズは米国の医薬品会社。急性疼痛や突出痛用の治療薬の開発と商業化に重点を置く。候補薬には入院患者向け急性痛自己治療システム「Zalviso」、および救急処置室や救急病院用の中度・重度疼痛治療のスフェンタニルナノ粒子錠剤がある。本社はカリフォルニア州。   AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the development and commercialization of therapies for the treatment of acute pain.
本社所在地 351 Galveston Drive Redwood City CA 94063 USA
代表者氏名 Adrian Adams エイドリアンアダムス
代表者役職名 Independent Chairman of the Board
電話番号 +1 650-216-3500
設立年月日 38534
市場名 NASDAQ National Market System
ipoyear 2011年
従業員数 41人
url www.acelrx.com
nasdaq_url https://www.nasdaq.com/symbol/acrx
adr_tso
EBITDA EBITDA(百万ドル) -31.00100
終値(lastsale) 2.99
時価総額(marketcap) 181193742.86
時価総額 時価総額(百万ドル) 160.58980
売上高 売上高(百万ドル) 3.38800
企業価値(EV) 企業価値(EV)(百万ドル) 215.42480
当期純利益 当期純利益(百万ドル) -10.92800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 AcelRx Pharmaceuticals Inc revenues decreased 80% to $1.2M. Net loss decreased 23% to $22.1M. Revenues reflect Collaboration agreement revenue decrease of 88% to $625K Contract and other decrease of 2% to $536K. Lower net loss reflects Research and development - Balancing val decrease of 45% to $6M (expense) General and Administrative - Balancing v decrease of 6% to $6.8M (expense).

 ACRXのテクニカル分析


 ACRXのニュース

   After Years Of Development, AcelRx's Dsuvia Has Finally Generated Revenue  2019-05-16
Last week, on Wednesday, May 8, AcelRx (NASDAQ: ACRX ) reported its financial results from the first quarter of 2019 . Though there has not been a huge amount of news to report since the company's last business update in March , it nevertheless appears that AcelRx is moving steadily along w…
   Week 18 Breakout Forecast: Short-Term Picks To Give You An Edge  2019-04-28
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 102 weeks of public selections as part of this ongoing live forward-testing. In…
   AcelRx to announce first quarter 2019 results and provide an update on the company's business on Wednesday, May 8th, 2019  2019-04-25 PR Newswire
REDWOOD CITY, Calif. , April 25, 2019 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Wednesday, May 8th, 2019 . AcelRx management will host a …
   Study links opioid prescriptions to marketing spend  2019-01-18
A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of prescriptions written by doctors, leading to a rise in opioid overdose deaths. More news on: Endo…
   Gevo, VFC among premarket gainers  2019-01-18
Gevo (NASDAQ: GEVO ) +45% on supplying its sustainable and renewable alcohol-to-jet fuel to Avfuel. More news on: Gevo, Inc., Bank OZK, V.F. Corporation, Stocks on the move, , Read more …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アセルRX・ファ―マシュ―ティカルズ ACRX AcelRx Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)